HomeStock SectorsBioTechWhat To Expect From...

What To Expect From Johnson & Johnson’s Q2 Earnings – Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson JNJ is set to release its second-quarter earnings on Wednesday, July 16. According to Benzinga Pro data, analysts estimate adjusted earnings of $2.68 per share and sales of $22.85 billion.

While overall estimates for 2025 and beyond show only slight increases, investor attention is expected to heavily center on the company’s updated 2025 guidance, the evolving impact of tariffs and biosimilars, and the progress of its pipeline and recent product launches.

Adding to the pre-earnings anticipation, Bank of America Securities (BofA) has already updated its revenue estimates for J&J for 2025 and beyond ahead of second-quarter earnings.

Also Read: FDA Issues Early Alert For Johnson & Johnson’s Abiomed Heart Pump Controllers

BofA analyst Tim Anderson notably highlighted that the major focus is expected to be updated 2025 guidance, tariff impact, biosimilar impact, and pipeline and launch progress.

BofA itself slightly increased its second-quarter 2025 revenue and EPS estimates by 1% due to improved foreign exchange rates. For the full year 2025, revenue estimates are up 1% and underlying EPS estimates are 2% higher, again largely driven by foreign exchange, with similar modest increases projected for the later 2020s (though partly offset by the Erleada IRA).

Despite these slight upward revisions, BofA maintains a Neutral rating and a price forecast of $61, deeming the stock fairly valued given its average long-term EPS growth and above-average P/E multiple.

In a Wednesday investor note, analyst Anderson also pointed out that Johnson & Johnson anticipates a $2 billion net headwind in 2025, spread throughout the year, impacting assets such as Stelara (in addition to biosimilar and price erosion), Tremfya, the Invega family, Spravato, Opsumit, Uptravi, and Erleada, while Xarelto is expected to benefit.

Furthermore, CFO Joseph Wolk has revised the estimated 2025 tariff impact down to $200 million from the $400 million guided in the first quarter of 2025, with the majority weighted toward the second half of the year; this estimate does not factor in any potential Section 232 tariffs.

Earlier in July, a federal court sided with the U.S. Department of Health and Human Services (HHS), rejecting Johnson & Johnson’s attempt to alter its participation in the 340B Drug Pricing Program.

The dispute centers on the 340B Program, a federal initiative requiring pharmaceutical manufacturers participating in Medicaid and Medicare Part B to sell outpatient drugs at reduced prices to certain healthcare providers, including hospitals and clinics serving low-income and rural populations.

Price Action: JNJ stock is trading lower by 0.18% to $155.51 at last check Wednesday.

Read Next:

Image via Shutterstock

Most Popular

More from Author

A Big Piece of the BBB Puzzle: Lower Interest Rates

With published today, most Fed members eye this year,...

Nvidia Hits $4 Trillion Market Cap, Dow Jones Near ATH, Tariff and FOMC News

Nvidia (NASDAQ:) hit a $4 trillion market value on Wednesday, becoming...

Why OPEC+ Is Pumping Oil Fast and Playing Hardball

OPEC+ blindsided oil market participants, again, with a larger-than-expected oil production...

Read Now

A Big Piece of the BBB Puzzle: Lower Interest Rates

With published today, most Fed members eye this year, but are split on what are the next steps.  One must cynically wonder which of the members is eyeing Powell’s job.  President Trump has made no secret of how much he wants rate cuts, to the point of...

Nvidia Hits $4 Trillion Market Cap, Dow Jones Near ATH, Tariff and FOMC News

Nvidia (NASDAQ:) hit a $4 trillion market value on Wednesday, becoming the first public company to do so. Its stock rose 2.4% to $164, driven by strong demand for AI technology. Nvidia first passed the $2 trillion mark in February 2024, and first passed the $3 trillion mark...

Why OPEC+ Is Pumping Oil Fast and Playing Hardball

OPEC+ blindsided oil market participants, again, with a larger-than-expected oil production hike for August. Instead of the widely expected 411,000 barrels per day (bpd), the group of eight OPEC+ producers led by Saudi Arabia and Russia decided to add 548,000 bpd to their combined oil output next month. OPEC+...

Massive 69.4% Surge for IGC Pharma in After-Hours Trading: Here’s Why – IGC Pharma (AMEX:IGC)

IGC Pharma Inc IGC witnessed a surge of 69.40%  in its stock value during after-hours trading on Wednesday.What Happened: The stock of IGC Pharma, a company involved in the development of cannabinoid-based therapies for Alzheimer‘s disease, rose by 69.40% to $0.62. This surge followed the closing price...

Why Is Kazia Stock Soaring Today – Kazia Therapeutics (NASDAQ:KZIA)

Kazia Therapeutics KZIA on Wednesday reported preliminary results from the first patient in its Phase 1b trial evaluating a combination regimen of Paxalisib, Merck & Co Inc’s MRK Keytruda (pembrolizumab), and standard chemotherapy after completing Cycle 1 (21 days) of dosing.The patient, a 61-year-old woman with metastatic...

What To Expect From Eli Lilly’s Q2 Earnings – Eli Lilly (NYSE:LLY)

Eli Lilly and Co. LLY is set to release its second-quarter earnings on August 7. According to Benzinga Pro data, analysts are anticipating adjusted earnings of $5.56 per share and sales of $14.4 billion.Expectations are slightly higher for the quarter, primarily driven by the strong performance of its obesity...

Amazon, Defense Stocks in Spotlight Amid Trade and Consumer Uncertainty

US stocks are modestly higher as investors weigh up the latest announcements from President Trump and watch for further trade developments. President Trump announced plans to impose 50% tariffs on imports, sending prices sharply higher. US copper prices shot 13% higher, closing at a record high of...

Rhythm Pharma’s Oral Drug For Rare Obesity Shows Promise – Rhythm Pharmaceuticals (NASDAQ:RYTM)

Rhythm Pharmaceuticals, Inc. RYTM on Wednesday released topline results from its Phase 2 trial evaluating bivamelagon (formerly LB54640), an investigational oral melanocortin-4 receptor (MC4R) agonist, in patients with acquired hypothalamic obesity.Hypothalamic obesity is a rare type of obesity resulting from damage to the hypothalamus, a brain region...

Risk Assets Rebound as Trump Pushes Tariff Deadline to August 1

After a volatile past day session, this one was way calmer as Trump announced yet another delay in tariff deadlines – From the approaching July 9th to August 1st, apparently the final warning. The session began with the leading to the upside, followed by general mean-reversion all...

Gilead’s Lenacapavir Plan Faces Global Hurdles As It Commits To No-Profit Access for 2 Million – Gilead Sciences (NASDAQ:GILD)

Gilead Sciences, Inc. GILD on Wednesday announced a strategic partnership agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria to supply lenacapavir — Gilead’s twice-yearly injectable HIV-1 capsid inhibitor — for the prevention of HIV as pre-exposure prophylaxis (PrEP).Through the agreement, Gilead will supply enough...

Markets Today: RBNZ Rate Hold, Copper Volatility, DAX Moves Toward Fresh Highs

Chinese stocks are set to hit their highest level in three years as investors hope for new steps to fight deflation and boost the economy. Meanwhile, dropped in London after President Donald Trump issued a new tariff warning.Asian Market WrapThe Shanghai Stock Exchange Composite Index rose...

FDA Approves New Dosing Schedule For Eli Lilly’s Kisunla In Alzheimer’s Treatment – Eli Lilly (NYSE:LLY)

The U.S. Food and Drug Administration (FDA) has approved a label update with a new recommended titration dosing schedule for Eli Lilly and Co.’s LLY Kisunla (donanemab-azbt) once-monthly amyloid-targeting therapy for adults with early symptomatic Alzheimer’s disease (AD). The FDA approved the drug in July 2024.In the TRAILBLAZER-ALZ 6...